Deuruxolitinib (Leqselvi) for Severe Alopecia Areata
The FDA has approved the oral Janus kinase (JAK) inhibitor deuruxolitinib (Leqselvi – Sun) for treatment of severe alopecia areata in adults. Two other oral JAK inhibitors are approved for treatment of severe alopecia areata: baricitinib (Olumiant) is approved for use in adults,1 and ritlecitinib (Litfulo) is approved for use in patients ≥12 years old.
Publication Details
- Journal
- The medical letter on drugs and therapeutics/The medical letter
- Published
- 2025-10-09
- DOI
- https://doi.org/10.58347/tml.2025.1740b
- Primary Topic
- Dupuytren's Contracture and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00